Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program.

Autor:	Moehler, Markus1 markus.moehler@unimedizin-mainz.de, Gepfner-Tuma, Irina1, Maderer, Annett1, Thuss-Patience, Peter C.2, Ruessel, Joern3, Hegewisch-Becker, Susanna4, Wilke, Hansjochen5, Al-Batran, Salah-Eddin6, Rafiyan, Mohammad-Reza6, Weiβinger, Florian7, Schmoll, Hans-Joachim3, Kullmann, Frank8, von Weikersthal, Ludwig Fischer9, Siveke, Jens T.10, Weusmann, Jens1, Kanzler, Stephan11, Schimanski, Carl Christoph12, Otte, Melanie13, Schollenberger, Lukas14, Koenig, Jochem15
Zdroj:	BMC Cancer. 8/31/2016, Vol. 16, p1-13. 13p. 1 Diagram, 4 Charts, 4 Graphs.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu